BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 15250020)

  • 21. [Antimicrobial therapy of febrile neutropenia--current developments].
    Karthaus M; Cornely OA; Südhoff T; Meran J
    Wien Med Wochenschr; 2001; 151(3-4):66-72. PubMed ID: 11789421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antibiotic therapy in leukopenia].
    Böhme A; Shah PM; Stille W; Hoelzer D
    Praxis (Bern 1994); 1998 Sep; 87(36):1120-5. PubMed ID: 9782739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia.
    Tamura K; Imajo K; Akiyama N; Suzuki K; Urabe A; Ohyashiki K; Tanimoto M; Masaoka T;
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S15-24. PubMed ID: 15250016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Infections in neutropenic patients].
    Berenguer J
    Enferm Infecc Microbiol Clin; 1995 Feb; 13(2):113-20. PubMed ID: 7711117
    [No Abstract]   [Full Text] [Related]  

  • 25. Empirical antifungal therapy in treating febrile neutropenic patients.
    Wingard JR
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S38-43. PubMed ID: 15250019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diagnostic procedures and management of Fever in pediatric cancer patients].
    Laws HJ; Ammann RA; Lehrnbecher T
    Klin Padiatr; 2005 Nov; 217 Suppl 1():S9-16. PubMed ID: 16288350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empirical therapy of infections in neutropenic patients.
    Gaya H
    Br J Haematol; 1998 May; 101 Suppl 1():5-9. PubMed ID: 9607734
    [No Abstract]   [Full Text] [Related]  

  • 28. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens.
    Ramphal R
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S25-31. PubMed ID: 15250017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients.
    Fleming DR; Ziegler C; Baize T; Mudd L; Goldsmith GH; Herzig RH
    Am J Clin Oncol; 2003 Jun; 26(3):285-8. PubMed ID: 12796602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Empiric therapy for febrile neutropenia: what are the choices?
    Aoun M
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):507-15. PubMed ID: 17547514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification.
    Viscoli C; Varnier O; Machetti M
    Clin Infect Dis; 2005 Apr; 40 Suppl 4():S240-5. PubMed ID: 15768329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
    Safdar A; Rodriguez GH; Lichtiger B; Dickey BF; Kontoyiannis DP; Freireich EJ; Shpall EJ; Raad II; Kantarjian HM; Champlin RE
    Cancer; 2006 Jun; 106(12):2664-71. PubMed ID: 16691620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibiotics in 30 minutes or less for febrile neutropenic patients: a quality control measure in a new hospital.
    Corey AL; Snyder S
    J Pediatr Oncol Nurs; 2008; 25(4):208-12. PubMed ID: 18539908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Managing infections in the immunocompromised patient.
    Bodey GP
    Clin Infect Dis; 2005 Apr; 40 Suppl 4():S239. PubMed ID: 15768328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey.
    Yoshida M; Ohno R
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S11-4. PubMed ID: 15250015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer.
    Akova M; Paesmans M; Calandra T; Viscoli C;
    Clin Infect Dis; 2005 Jan; 40(2):239-45. PubMed ID: 15655741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and microbiologic determinants of serious bloodstream infections in Egyptian pediatric cancer patients: a one-year study.
    El-Mahallawy H; Sidhom I; El-Din NH; Zamzam M; El-Lamie MM
    Int J Infect Dis; 2005 Jan; 9(1):43-51. PubMed ID: 15603994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic issues: toward a cost-effective approach to the management of febrile neutropenia in Japan.
    Masaoka T
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S68-9. PubMed ID: 15250026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
    Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
    J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Infectious complications in pediatric cancer patients].
    Lehrnbecher T; Laws HJ
    Klin Padiatr; 2005 Nov; 217 Suppl 1():S3-8. PubMed ID: 16288349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.